Nutritional and medicinal oral composition for veterinary use
The invention relates to a method for producing a nutritional and medicinal oral composition for veterinary use, comprising the following steps: a) providing cores of extruded products of complete feed, and b) coating the cores of extruded products of complete feed provided in step a) with at least one layer of a fatty material comprising at least one medicinal agent, said medicinal agent comprising (i) at least one pre-conditioned active substance in the form of a solution or a suspension of said active substance in an oily liquid, or (ii) at least one pre-conditioned active substance in the form of waxy granulates, at a temperature lower than 40° C.
1. A method for obtaining a nutritional and medicinal oral composition for veterinary use comprising the following steps:
a) supplying cores of complete feed extrudate,
b) providing a medicinal agent selected in the group consisting of (i) at least one active principle in the form of non-encapsulated microparticles preconditioned in the form of a solution or a suspension of the active principle in an oily liquid or providing (ii) at least one active principle in the form of non-encapsulated microparticles preconditioned in the form of waxy granules, wherein the active principle is selected from angiotensin-converting enzyme inhibitors (ACE inhibitors), renin inhibitors, angiotensin II receptor antagonists, firocoxib, ciclosporin, S-adenosyl-methionine, eplerenone, spironolactone, amlodipine and levosimendan,
b1) bringing the cores of complete feed extrudate into contact with the medicinal agent, and
b2) coating the extrudate cores obtained at the end of step b1) with at least one layer of fat, at a temperature below 40° C.
2. The method as claimed in claim 1 , wherein the layer of fat comprises at least one fat of animal or vegetable origin.
3. The method as claimed in claim 1 , wherein the layer of fat is solid at a temperature below 25° C.
4. The method as claimed in claim 1 , wherein the layer of fat comprises at least one fat selected from hog fat, lard, suet, duck fat or fish oil.
5. The method as claimed in claim 1 , wherein the medicinal agent is an active pharmaceutical ingredient that is sensitive to moisture.
6. The method as claimed in claim 1 , wherein the medicinal agent is an active pharmaceutical ingredient that is intended for reducing the likelihood of developing a chronic disorder or disease or for treating a chronic disorder or disease.
7. The method as claimed in claim 1 , wherein the medicinal agent is an active pharmaceutical ingredient that is intended for reducing the likelihood of developing renal insufficiency or for treating renal insufficiency.
8. The method as claimed in claim 1 , wherein the angiotensin-converting enzyme inhibitors are selected from benazepril, enalapril, ramipril, quinapril, preindopril, lisinopril, imidapril, zofnopril, trandolapril, as well as salts thereof.
9. The method as claimed in claim 8 , wherein the angiotensin-converting enzyme inhibitor is benazepril or salt thereof, in particulate form.
10. The method as claimed in claim 1 , wherein the renin inhibitors are selected from pepstatin, peptide analogs of pepstatin, peptide mimetics of pepstatin and non-peptide mimetics of pepstatin, as well as salts thereof.
11. The method as claimed in claim 1 , wherein the angiotensin II receptor antagonists are selected from valsartan, telmisartan, losartan, irbesartan, azilsartan and omesartan, as well as salts thereof.
12. A method for obtaining a nutritional and medicinal oral composition for veterinary use comprising the following steps:
a) supplying cores of complete feed extrudate, and
b) providing a medicinal agent selected in the group consisting of (i) at least one active principle in the form of non-encapsulated microparticles preconditioned in the form of a solution or a suspension of said active principle in an oily liquid or providing (ii) at least one active principle in the form of non-encapsulated microparticles preconditioned in the form of waxy granules, wherein the active principle is selected from angiotensin-converting enzyme inhibitors (ACE inhibitors), renin inhibitors, angiotensin II receptor antagonists, firocoxib, ciclosporin, S-adenosyl-methionine, eplerenone, spironolactone, amlodipine and levosimendan,
b3) obtaining a fat composition comprising the said medicinal agent, and
b4) coating the extrudate cores obtained at the end of step a) with at least one layer of the fat composition comprising said active principle obtained at the end of step b3), at a temperature below 40° C.